Echocardiographic markers of cardiac amyloidosis in patients with heart failure and left ventricular hypertrophy

Polo, Jorge Melero; Unceta-Barrenechea, Ana Roteta; Martí, Pablo Revilla; Pérez-Palacios, Raquel; Gutiérrez, Anyuli Gracia; Juana, E. Bueno; Gracia, Alejandro Andrés; Ayala, Saida Atienza; Arregui, Miguel Ángel Aibar

doi:10.5603/cj.a2021.0085

Search citation statements

Order By: Relevance

Paper Sections

Select...

Results1

Conventional Echocardiographic Findings Of Ca1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

2024

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 6 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…is provided in Table 1 8–25,34–77 . A graphical representation of the prevalence of cardiac amyloidosis across various populations subgroups is provided in Figure (and online supplementary Figure – focused version).…”

Section: Resultsmentioning

confidence: 99%

Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta‐analysis

Antonopoulos

Panagiotopoulos

Kouroutzoglou

et al. 2022

European J of Heart Fail

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta‐analysis

Antonopoulos

Panagiotopoulos

Kouroutzoglou

et al. 2022

European J of Heart Fail

View full text Add to dashboard Cite

show abstract

“…LV hypertrophy (LVH) is CA patients’ most common echocardiographic finding (Fig. 3 A) [ 10 ]. It was reported that with the help of gene detection, nearly 5% of the patients initially diagnosed with hypertrophic cardiomyopathies were eventually diagnosed as ATTRm [ 11 ].…”

Section: Conventional Echocardiographic Findings Of Camentioning

confidence: 99%

Advance of echocardiography in cardiac amyloidosis

Liang

Liu

et al. 2023

Heart Fail Rev

View full text Add to dashboard Cite

Cardiac amyloidosis (CA) occurs when the insoluble fibrils formed by misfolded precursor proteins deposit in cardiac tissues. The early clinical manifestations of CA are not evident, but it is easy to progress to refractory heart failure with an inferior prognosis. Echocardiography is the most commonly adopted non-invasive modality of imaging to visualize cardiac structures and functions, and the preferred modality in the evaluation of patients with cardiac symptoms and suspected CA, which plays a vital role in the diagnosis, prognosis, and long-term management of CA. The present review summarizes the echocardiographic manifestations of CA, new echocardiographic techniques, and the application of multi-parametric echocardiographic models in CA diagnosis.

show abstract

Evaluation of demographic, clinical, and aetiological data of patients admitted to cardiology clinics and diagnosed with left ventricular hypertrophy in Turkish population (LVH-TR)

et al. 2022

View full text Add to dashboard Cite

Echocardiographic markers of cardiac amyloidosis in patients with heart failure and left ventricular hypertrophy

Abstract: This article has been peer reviewed and published immediately upon acceptance.It is an open access article, which means that it can be downloaded, printed, and distributed freely, provided the work is properly cited. Articles in "Cardiology Journal" are listed in PubMed.

Cited by 6 publications

References 30 publications

Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta‐analysis

Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta‐analysis

Advance of echocardiography in cardiac amyloidosis

Evaluation of demographic, clinical, and aetiological data of patients admitted to cardiology clinics and diagnosed with left ventricular hypertrophy in Turkish population (LVH-TR)

Contact Info

Product

Resources

About